Ropsohn Therapeutics SAS Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: Ropsohn Therapeutics SAS Pharmaceutical Import Records from India — 4 Products, $808.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ropsohn Therapeutics SAS — Pharmaceutical Importer Profile (2026) | 4 Products, $808.1K Trade | TransData Nexus

Ropsohn Therapeutics SAS

Pharmaceutical Importer · Colombia · Oncology Focus · $808.1K Total Trade · DGFT Verified

Ropsohn Therapeutics SAS is a pharmaceutical importer based in Colombia with a total trade value of $808.1K across 4 products in 2 therapeutic categories. Based on 36 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ropsohn Therapeutics SAS sources from 1 verified Indian supplier, with Medorbis Trade Llp accounting for 100.0% of imports.

Ropsohn Therapeutics SAS — Import Portfolio & Supplier Network

Ropsohn Therapeutics SAS import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ropsohn Therapeutics SAS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medorbis Trade Llp	$1.3M	67	100.0%

Ropsohn Therapeutics SAS sources from 1 verified Indian supplier across 40 distinct formulations. The sourcing is highly concentrated — Medorbis Trade Llp accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ropsohn Therapeutics SAS Import?

Formulation	Value	Ships
Etoposide injection USP 100MG 5ML	$100.0K	2
Fluorouracil injection BP 500MG 10ML 100000	$100.0K	2
Methotrexate tablets BP 2.5MG	$99.2K	4
Fluorouracil injection BP 500MG/10ML	$83.6K	10
Cisplatin injection BP 50MG 50ML	$76.9K	4
Docetaxel for injection concentrate 80MG	$64.0K	3
Cytarabine injection BP 500MG/5ML (30566vials	$61.1K	3
Gemcitabine injection 1000MG/100ML	$52.8K	3
Paclitaxel injection USP 100MG/16.67ML	$50.0K	1
Cytarabine injection BP 500MG 5ML	$50.0K	1
Paclitaxel injection USP 100MG/16.67ML	$50.0K	1
Cisplatin injection BP 50MG/50ML (16684vials)	$50.0K	1
Methotrexate tablets BP 2.5MG	$40.2K	2
Cisplatin injection BP 50MG/50ML	$35.5K	2
Paclitaxel injection USP 100MG/16.67ML	$34.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluorouracil	Oncology	$256.6K	15	2.1%	8
2	Cisplatin	Oncology	$202.3K	8	1.6%	12
3	Cytarabine	Advanced Oncology	$199.1K	10	1.9%	16
4	Etoposide	Oncology	$150.0K	3	1.4%	6

Ropsohn Therapeutics SAS imports 4 pharmaceutical products across 2 categories into Colombia totaling $808.1K.

Ropsohn Therapeutics SAS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ropsohn Therapeutics SAS is a Colombian pharmaceutical company specializing in the manufacturing of pharmaceutical products, including chemical substances and botanical products for pharmaceutical use. Established on April 3, 1972, the company is headquartered in Bogotá D.C., Colombia. Operating as a Sociedad por Acciones Simplificada (SAS), Ropsohn Therapeutics SAS has a net worth of approximately 287.6 billion COP and reported net sales revenue exceeding 100 billion COP in 2024. (directorio-empresas.einforma.co)

In the Colombian pharmaceutical distribution landscape, Ropsohn Therapeutics SAS plays a pivotal role as a manufacturer and importer of pharmaceutical products. The company's extensive import activities underscore its significant presence in the market, facilitating the availability of a diverse range of pharmaceutical formulations to meet the healthcare needs of the Colombian population.

2Distribution Network

While specific details regarding Ropsohn Therapeutics SAS's warehouse locations and logistics capabilities are not publicly disclosed, the company's substantial import activities suggest a well-established distribution network within Colombia. The strategic location of its headquarters in Bogotá D.C. positions the company advantageously for nationwide distribution, ensuring efficient delivery of pharmaceutical products across the country. The company's import data indicates a diverse sourcing strategy, with suppliers from various countries, including India, Germany, and Finland, reflecting a robust logistics framework capable of managing international supply chains.

3Industry Role

Ropsohn Therapeutics SAS operates primarily as a pharmaceutical manufacturer and importer within Colombia's pharmaceutical supply chain. The company's import data reveals a significant volume of pharmaceutical products, indicating its substantial role in supplying the Colombian market with essential medications. By importing a diverse array of pharmaceutical formulations, Ropsohn Therapeutics SAS contributes to the availability and accessibility of critical healthcare products, thereby enhancing the overall efficiency and responsiveness of Colombia's pharmaceutical distribution network.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ropsohn Therapeutics SAS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ropsohn Therapeutics SAS's import data indicates a notable concentration in its sourcing strategy, with a significant portion of imports originating from India. This single-source dependency may present risks related to supply chain disruptions, currency fluctuations, and geopolitical factors affecting trade relations. However, the company's diversified product portfolio, encompassing multiple therapeutic categories and formulations, suggests a strategic approach to mitigate potential risks associated with supplier concentration. The stability of the relationship with Indian suppliers, as evidenced by consistent import volumes, further indicates a reliable and established supply chain partnership.

2Supply Chain Resilience

Ropsohn Therapeutics SAS's reliance on Indian suppliers for a substantial portion of its pharmaceutical imports necessitates a thorough assessment of supply chain resilience. The company's import data reveals a diverse range of formulations, which may help mitigate risks associated with over-reliance on a single supplier. However, the absence of publicly available information regarding backup suppliers and specific shipping routes limits the ability to fully evaluate the robustness of the supply chain. Ensuring compliance with international regulatory standards, such as WHO Good Manufacturing Practices (GMP), is crucial for maintaining product quality and mitigating potential disruptions.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the National Food and Drug Surveillance Institute (INVIMA) serves as the primary regulatory authority overseeing the importation, distribution, and commercialization of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Decree 2200 of 2005, which establishes the regulatory framework for the importation of pharmaceutical products, and the Decree 4725 of 2005, which outlines the requirements for the registration of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a sanitary registration from INVIMA, ensuring compliance with Colombian health and safety standards.

2Import Licensing & GMP

Import licensing requirements in Colombia stipulate that pharmaceutical importers must obtain a sanitary registration from INVIMA for each product intended for importation. This process involves submitting comprehensive documentation, including proof of Good Manufacturing Practice (GMP) certification from the country of origin. Colombia recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, importers must possess a wholesale distribution authorization issued by INVIMA, ensuring compliance with national distribution standards.

Ropsohn Therapeutics SAS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ropsohn Therapeutics SAS's focus on oncology and advanced oncology products aligns with the growing demand for cancer treatments in Colombia. The importation of key oncology medications, such as Fluorouracil, Cisplatin, Cytarabine, and Etoposide, reflects a strategic approach to address critical therapeutic needs. Market demand for these products is driven by increasing cancer incidence rates and the need for effective treatment options, positioning Ropsohn Therapeutics SAS as a key player in providing essential oncology therapies.

2Sourcing Profile

Ropsohn Therapeutics SAS's sourcing strategy emphasizes the importation of generic drugs, particularly in the oncology therapeutic area. The company's preference for finished pharmaceutical formulations, as opposed to raw active pharmaceutical ingredients (APIs), indicates a focus on ready-to-use products that meet Colombian regulatory standards. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for Ropsohn Therapeutics SAS's procurement needs.

3Market Positioning

Based on its product mix, Ropsohn Therapeutics SAS primarily serves the hospital and wholesale distribution segments of the Colombian market. The importation of specialized oncology medications positions the company to meet the needs of healthcare institutions and pharmacies requiring these critical therapies. By ensuring a steady supply of essential oncology drugs, Ropsohn Therapeutics SAS contributes to the overall healthcare infrastructure and patient care in Colombia.

Seller's Guide — How to Become a Supplier to Ropsohn Therapeutics SAS

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Ropsohn Therapeutics SAS, particularly in the oncology therapeutic area. The company's established import patterns and focus on specific formulations present avenues for expanding product offerings and strengthening market presence. Identifying gaps in Ropsohn Therapeutics SAS's current sourcing, such as unmet therapeutic needs or emerging treatment options, can provide strategic entry points for new suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply Ropsohn Therapeutics SAS and the Colombian market must ensure compliance with INVIMA's regulatory requirements, including obtaining GMP certifications recognized by international bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet Colombian labeling standards, including Spanish language requirements and serialization mandates. Establishing a partnership with a local distributor or agent familiar with Colombian import regulations can facilitate market entry and ensure adherence to all necessary standards.

3How to Approach

Frequently Asked Questions — Ropsohn Therapeutics SAS

What products does Ropsohn Therapeutics SAS import from India?

Ropsohn Therapeutics SAS imports 4 pharmaceutical products across 2 categories. Top imports: Fluorouracil ($256.6K), Cisplatin ($202.3K), Cytarabine ($199.1K), Etoposide ($150.0K).

Who supplies pharmaceuticals to Ropsohn Therapeutics SAS from India?

Ropsohn Therapeutics SAS sources from 1 verified Indian suppliers. The primary supplier is Medorbis Trade Llp (100.0% of imports, $1.3M).

What is Ropsohn Therapeutics SAS's total pharmaceutical import value?

Ropsohn Therapeutics SAS's total pharmaceutical import value from India is $808.1K, based on 36 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ropsohn Therapeutics SAS focus on?

Ropsohn Therapeutics SAS imports across 2 categories. The largest: Oncology (75.4%), Advanced Oncology (24.6%).

Get Full Ropsohn Therapeutics SAS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.